Cc1c(-c2ccc(Br)cc2)[n+]([O-])c2c([n+]1[O-])CCCC2
The rule of three is typically followed by orally active drugs, which have a molecular weight of <300, a c LogP of ≤3, a hydrogen bond donor count of ≤3 and a hydrogen bond acceptor count of ≤3. Does the molecule comply with the rule of three?